Guanhao Biotech Co (SZSE:300238) Accounts Payable & Accrued Expense : ¥85.4 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Guanhao Biotech Co Accounts Payable & Accrued Expense?

Guanhao Biotech Co's quarterly accounts payable & accrued expense increased from Sep. 2023 (¥102.9 Mil) to Dec. 2023 (¥118.8 Mil) but then declined from Dec. 2023 (¥118.8 Mil) to Mar. 2024 (¥85.4 Mil).

Guanhao Biotech Co's annual accounts payable & accrued expense declined from Dec. 2021 (¥128.2 Mil) to Dec. 2022 (¥102.2 Mil) but then increased from Dec. 2022 (¥102.2 Mil) to Dec. 2023 (¥118.8 Mil).

Guanhao Biotech Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Guanhao Biotech Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guanhao Biotech Co Accounts Payable & Accrued Expense Chart

Guanhao Biotech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

93.07

121.24

128.24

102.19

118.84

Guanhao Biotech Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															104.23	95.70	102.88	118.84	85.39

Guanhao Biotech Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Guanhao Biotech Co (SZSE:300238) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guanhao Biotech Co Ltd (SZSE:300238) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.12 Yuyan Road, Luogang District, Guangdong, Guangzhou, CHN, 510530

Website

http://www.grandhopebio.com

Guanhao Biotech Co Ltd is a China-based biotech company. It develops, manufactures and markets life and health-related products, with focus on regenerative medicines for the treatment of damaged tissue and organs. Its products include NormalGEN dura repair patch, GrandNeuro (Type B) dura repair patch, ThromalGEN (Type P) surgical patch, Guanhao-ACI, among others.

Executives

Liu De Wang	Directors, executives
Zhao Jun Hui	Directors, executives
Yang Guo Sheng	Supervisors
Zhu Wei Ping	Director
Hu Jun	Securities Affairs Representative
Jia Bao Rong	Executives
Jia Jun Chao	Executives
Di Pu	Director
Zhuo Fu Min	Director
Guo Xiao Ming	Executives
Zhang Hong Tao	Executives
Zhao Wen Jie	Executives
Guan Xin	Director

Guanhao Biotech Co (SZSE:300238) Headlines

No Headlines